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Deregulation of apoptotic processes is likely one of the key factors contributing to the malignant nature of me-
lanoma marked by strong chemoresistance. X-linked inhibitor of apoptosis protein (XIAP) suppresses apoptosis
through the inhibition of various caspases. Recently, XIAP-associated factor 1 (XAF1) has been identiﬁed as a
XIAP-binding protein that antagonizes the anti-apoptotic activity of XIAP. In this study, we sought to determine the
role of XAF1 in melanoma progression. Analysis of XAF1 mRNA expression in melanoma cell lines revealed that
XAF1 mRNA was downregulated in 15 of 16 cell lines examined. We next evaluated XAF1 protein expression on a
tissue microarray representing 40 benign nevi and 70 primary melanomas. Our results showed that XAF1 expres-
sion in melanoma tissues was significantly reduced compared with benign melanocytic nevi (po0.05). Our data
also demonstrated that the substantial reduction of XAF1 expression occurred in both nucleus and cytoplasm in
the tumor cells (po0.0001 for both). Reduced XAF1 expression, however, was not significantly correlated with
tumor thickness and 5-y patient survival. Further studies are required to understand the molecular mechanisms
governing the selective loss of XAF1 expression in the tumor tissue.
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Cutaneous melanoma is a highly aggressive skin cancer
derived from malignant transformation of epidermal me-
lanocytes as a result of complex interactions between
constitutional, genetic, and environmental factors. The in-
cidence of melanoma has risen dramatically in the Cauca-
sian population over the past decades, surpassing other
cancers and only in recent years there has been an evi-
dence of stabilization in certain populations (Bevona and
Sober, 2002; Desmond and Soong, 2003; Tucker and Gold-
stein, 2003). In 2003, melanoma was the fifth and seventh
most common cancer in men and women, respectively, in
the United States (Jemal et al, 2003). The lifetime cumula-
tive risk of developing melanoma is 1 in 57 for men and 1 in
82 for women (Jemal et al, 2003). The highly malignant na-
ture of melanoma is characterized by the capability of the
melanoma cells to invade into deeper dermis and underly-
ing subcutaneous tissues and the rapid metastasis to al-
most any organ. Metastatic melanoma is associated with a
poor prognosis and a median survival of only 6–9 mo (Lee
et al, 2000). The drastic decease in survival rate at the ad-
vanced stage of the disease is explained by the lack of
effective treatment. The high successful rate of surgical re-
section is only restricted to localized melanomas. Radiation
and chemotherapies have limited response on melanoma
patients. Dacarbazine (DTIC), the most active single agent
for treatment of malignant melanoma yields response rates
of only 20% with a short lived median response duration of
6 mo (Nathan and Mastrangelo, 1998; Chowdhury et al,
1999; Pavlick, 2002). Combination chemotherapy alone or
with immunological adjuvant also offers no survival advan-
tage (Nathan and Mastrangelo, 1998; Chowdhury et al,
1999; Pavlick, 2002). The highly invasive behavior and the
resistance to a wide-range of chemotherapeutic agents
have prompted for further understanding of the molecular
mechanism of malignant tumor progression and chemo-
resistance. Characterization of changes occurring in the
malignant cells is therefore important for the development
of new therapeutic strategy.
Tumor cell death in response to cytotoxic agents appears
to result from the induction of apoptosis, which is an es-
sential process for eliminating cells that are redundant,
damaged or potentially dangerous (Schmitt and Lowe,
1999). Deregulation of this process may be a contributing
factor to chemoresistance. One of the key regulators of
apoptosis belongs to a family of proteins known as inhibitor
of apoptosis (IAP), characterized by the presence of one or
more conserved baculovirus IAP repeat (BIR) domains
(Salvesen and Duckett, 2002; Liston et al, 2003). To date,
eight members of the IAP family have been identified. The
anti-apoptotic function of certain members has been at-
tributed to the direct binding and inhibition of caspases
(Deveraux et al, 1997; Roy et al, 1997; Kasof and Gomes,
2001; Shin et al, 2001; Maier et al, 2002). Of the known IAP,
X-linked inhibitor of apoptosis (XIAP) protein is the best
characterized and the most potent inhibitor of apoptosis.
XIAP is widely expressed in most adult and fetal tissues
(Liston et al, 1996). XIAP inhibits the initiator caspase-9
Abbreviations: IAP, inhibitor of apoptosis; PBS, phosphate-buff-
ered saline; XAF1, XIAP-associated factor 1; XIAP, X-linked inhib-
itor of apoptosis
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through direct interaction with its third BIR domain (Sri-
nivasula et al, 2001). The inhibitory activity of XIAP to the
effector caspases, caspase-3 and -7, is localized to the
linker region preceding the second BIR domain (Huang et al,
2001). The caspases-inhibitory activity of XIAP is likely to
account for the protective effect against a wide spectrum of
apoptotic triggers including serum withdrawal, ultraviolet
irradiation, tumor necrosis factor, Fas ligand, Bax overex-
pression, and a number of anti-cancer drugs (LaCasse et al,
1998).
The anti-apoptotic activity of XIAP is negatively regulated
by two mitochondrial proteins: Smac/DIABLO and HtrA2/
Omi. Both proteins are released to the cytosol along with
cytochrome c during mitochondrial destabilization in re-
sponse to apoptotic stimuli. Proteolytic cleavage of mi-
tochondrial targeting sequence generates an amino
terminal tetrapeptide, which is crucial for Smac/DIABLO
and HtrA2/Omi to interact and inhibit XIAP by sterically
preventing the XIAP-caspase interaction (Du et al, 2000;
Suzuki et al, 2001; Hegde et al, 2002; Martins et al, 2002;
Verhagen et al, 2002). Recently, a novel XIAP binding protein
termed XIAP-associated factor 1 (XAF1) has been identified
using a two hybrid system (Liston et al, 2001). XAF1 is a
301-amino-acid nuclear protein containing seven zinc fin-
gers. Biochemical study has shown that XAF1 is able to
block the XIAP-mediated inhibition of caspase-3 (Liston
et al, 2001). XAF1 was found to reverse the anti-apoptotic
effect of XIAP in response to apoptotic stimuli triggered by
serum withdrawal and etoposide treatment (Liston et al,
2001). A report has also identified XAF1 as an interferon-
inducible protein that can sensitize cells to TRAIL-induced
apoptosis (Leaman et al, 2002). Intriguingly, XAF1 mRNA is
ubiquitously expressed in normal human tissue but is low or
missing in majority of cancer cell lines, thus suggesting the
loss of XAF1 as part of the tumorigenesis process. Here, we
used tissue microarray (TMA) to evaluate the XAF1 expres-
sion in human primary melanoma. Our results demonstrate
that both the intensity of XAF1 staining and the percentage
of XAF1 positive cells were reduced in majority of me-
lanoma tissues. Since XAF1 binds to XIAP and inhibits the
anti-apoptotic function of XIAP, reduced XAF1 expression
may deregulate the normal apoptotic process and contrib-
ute to the highly malignant nature of melanoma.
Results
Reduced XAF1 expression in melanoma cell lines Using
NCI 60 cell line panel, the previous study has shown that
XAF1 RNA expression was lost in majority of cancer cell
lines (Fong et al, 2000). To determine the expression level of
XAF1 in melanoma, we characterized XAF1 mRNA expres-
sion in 16 melanoma cell lines using RT-PCR. XAF1 mRNA
expression was very weak or undetectable in 9 melanoma
cell lines (Fig 1). Six melanoma cell lines had a reduced
expression of XAF1 transcript and only one cell line (Sk-
mel-24) expressed high level of XAF1 comparable to the
normal human epidermal melanocyte.
Cells overexpressing XAF1 protein has revealed that ex-
ogenous XAF1 resides in the nucleus (Liston et al, 2001). To
determine the subcellular localization of the endogenous
XAF1, we performed indirect immunofluorescence. In nor-
mal melanocyte, high level of XAF1 protein can be detected
in both the cell body and the projection, with majority of
endogenous XAF1 densely packed in the nucleus (Fig 2). In
melanoma cells, XAF1 protein can also be visualized in both
nuclear and cytoplasm, but the staining intensity was sig-
nificantly reduced in the melanoma cell lines examined, es-
pecially in MMAN cells.
Clinicopathological features To determine whether aber-
rant XAF1 expression also occurs in primary melanoma, we
evaluated XAF1 protein expression in a tissue microarray
containing 87 primary melanomas using immunohistochem-
ical method. Of the 70 cases that were informative, there
were 38 male and 32 female. The mean age of the patients
was 56.7 y ranging from age 21 to 92. Breslow thickness,
which measures from the top layer of epidermis to the
deepest point of tumor penetration, was used as the criteria
for melanoma staging (Marghoob et al, 2000). Among the 70
informative cases, 16 were p0.75 mm, 39 were 0.76–1.5
mm, 9 were 1.51–4.0 mm, and 6 were >4.0 mm (Table I).
Superficial spreading melanoma accounted for 32 cases,
lentigo maligna melanoma accounted for 11 cases, and the
remaining 27 cases consisted of nodular melanoma,
acrolentigous melanoma, and desmoplastic melanoma.
The majority of the melanomas were isolated from sun-pro-
tected sites (56 cases; trunk, arm leg, and feet) and 14
Figure 1
Expression of XIAP-associated factor 1 (XAF1) transcript in melanoma cell lines. RT-PCR was performed and the 324 bp PCR products were
resolved on a 2% agarose gel. GAPDH was used as an endogenous control. PCR products amplified from 200 ng of XAF1 expression plasmid
served as the positive control. For the negative control, RT-PCR was performed in the same manner except RNA was omitted from the reaction.
XAF1 expression was very weak or undetectable in nine cell lines (PED1, MMAN, MeWo, PMWK, KZ-2, KZ-28, Sk-mel-3, Sk-mel-5, and Sk-mel-
110). Six cell lines (MMRU, RPEP, KZ-13, Sk-mel-2, Sk-mel-93, and Sk-mel-28) showed a reduced expression of XAF1 mRNA. Sk-mel-24 had an
expression level similar to normal melanocytes. NHEM, normal human epidermal melanocyte.
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cases were obtained from sun-exposed sites (head and
neck).
Reduction of XAF1 protein expression in primary me-
lanoma To determine whether XAF1 is specifically reduced
in melanoma, we set out to compare the overall intensity of
XAF1 staining between the tumor and benign nevi. Among
the primary melanomas, XAF1 was weakly expressed in 23
cases (32.9%), moderately expressed in 31 cases (44.3%)
and highly expressed in 16 cases (22.9%) (Fig 3). In con-
trast, 37.5% of the informative nevi cases (15 of 40) showed
a high expression of XAF1, 50% of the cases (20 of 40)
showed a moderate expression, and only 12.5% of the nevi
(5 of 40) showed a weak expression. None of the tumor and
nevi were negative for XAF1. The reduction of XAF1 ex-
pression in primary melanoma was found to be statistically
significant (po0.05, w2 test) (Fig 3e).
We also examined the percentage of cells showing pos-
itive XAF1 staining in the nucleus and cytoplasm for both
nevi and tumor cells. Weaker staining intensities in tumor
cells were associated with fewer positive XAF1 staining in
the nucleus (p¼0.046, w2 test) (Table I). Weak nuclear pos-
itivity was observed in 81.4% of all melanoma cases (57 of
70). On the other hand, only 17.5% of the cases were
weakly positive (7 of 40) in the normal nevi tissue and the
rest of the cases showed strong nuclear positivity (33 of 40,
82.5%). On average, nuclear XAF1 staining was seen in
28.1% of melanoma cells, which is significantly lower than
68.4% seen in the nevi tissue (po0.0001, Mann–Whitney
test) (Fig 4a). For cytoplasmic staining, weaker staining in-
tensity in the tumors was also associated with a corre-
sponding decrease in the percentage of cells containing
positive cytoplasmic staining (p¼ 0.0281, w2 test) (Table I).
As many as 33 of 70 melanoma cases (47%) were weakly
positive in the cytoplasm; in contrast, most of the 40 nevi
cases (36 of 40, 90%) were strongly positive. Similar to the
Figure 2
Nuclear and cytoplasmic distribution of XIAP-associated factor 1
(XAF1) in melanoma cell lines and melanocytes. Subcellular local-
ization of XAF1 was visualized by performing indirect immunofluores-
cence. Cells were stained using a rabbit anti-XAF1 antibody and the
nuclei were stained with Hoechst 33258. Scale bar¼ 10 mm
Figure3
Differential XIAP-associated factor 1 (XAF1) expression in human
cutaneous melanoma. (a) Normal nevi showing strong XAF1 expres-
sion (3þ ). (b–d) Melanoma showing weak XAF1 expression (1þ ),
moderate XAF1 expression, and strong XAF1 expression (3þ ), re-
spectively. Scale bar¼10 mm. (e) XAF1 staining is significantly reduced
in tumor tissues compared to benign nevi. po0.05, w2 test.
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nuclear reduction, cytoplasmic staining was also found to
be significantly reduced as we observed that cytoplasmic
XAF1 staining was seen in 54.2% of melanoma cells on
average, which is significantly lower than 83.3% in the nevi
tissue (po0.0001, Mann–Whitney test) (Fig 4b). Although
the reduction in cytoplasmic staining is prevalent in tumor
tissues, cytoplasmic XAF1 was still found in substantial
portion of cells (54.2%).
XAF1 expression and clinical parameters The clinical
outcome of melanoma patients are strongly influenced by
the depth of invasion. When we examined XAF1 staining
intensity at different tumor thicknesses, we found no asso-
ciation existed between XAF1 intensity and tumor thickness
(p¼0.119, w2). Interestingly, when we examined the per-
centage of cells positive for nuclear staining at different
tumor thicknesses, we found that thicker tumor tended to
have a greater reduction of nuclear XAF1 expression, al-
though the difference was not statistically significant
(p¼0.156, Kruskal–Wallis test) (Fig 5a). Analysis of XAF1
expression and other clinical characteristics including gen-
der, age, location of tumors, and histological subtype did
not reveal any significant association (Table I). Since the
XAF1 expression was reduced in majority of melanoma
tumors, we plotted Kaplan–Meier survival curves to
determine if any correlation existed between XAF1 expres-
sion and patient outcome. Our analysis showed that
weakly and moderately stained tumors did not yield a poor-
er 5 y overall survival when compared with tumor biopsies
of strong staining (p¼0.889, log-rank test) (Fig 5b). In ad-
dition, the 5-y overall survival between tumors samples
showing strong nuclear positivity and weak nuclear posit-
ivity did not significantly differ (p¼0.896, log-rank test)
(Fig 5c).
Table I. XAF1 expression and clinicopathological
characteristics
Overall intensity
of XAF1 staining
Total p-value1þ 2þ 3þ
Age
 55 12 (35%) 14 (41%) 8 (24%) 34 40.05
455 11 (31%) 17 (47%) 8 (22%) 36
Gender
Male 11 (29%) 17 (45%) 10 (26%) 38 40.05
Female 12 (38%) 14 (44%) 6 (19%) 32
Nuclear positivity
 50% 15 (43%) 16 (46%) 4 (11%) 35 o0.05
450% 8 (23%) 15 (43%) 12 (34%) 35
Cytoplasmic positivity
 50% 16 (48%) 12 (36%) 5 (15%) 33 o0.05
450% 7 (19%) 19 (51%) 11 (30%) 37
Tumor thickness (mm)
 0.75 6 (38%) 5 (31%) 5 (31%) 16 40.05a
0.76–1.5 15 (38%) 17 (44%) 7 (18%) 39
1.51–4.0 1 (11%) 7 (78%) 1 (11%) 9
>4.0 1 (17%) 2 (33%) 3 (50%) 6
Tumor subtypeb
SSM 12 (38%) 11 (34%) 9 (28%) 32 40.05c
LMM 2 (18%) 8 (73%) 1 (9%) 11
Other 9 (33%) 12 (44%) 6 (22%) 27
Sited
Sun-
exposed
5 (36%) 7 (50%) 2 (14%) 14 40.05c
Sun-
protected
18 (32%) 24 (43%) 14 (25%) 56
aContingency table for low (1þ ), and moderate-to-high XAF1 expres-
sion (2þ , 3þ ) against thickness p1.5 and 41.5 mm.
bSSM, superficial spreading melanoma; LMM, lentigo maligna me-
lanoma; other includes desmoplastic melanoma, acrolentigous melanoma,
and nodular melanoma.
cw2 test for low (1þ ) versus moderate-to-high XAF1 expression (2þ ,
3þ ).
dSun-protected sites: trunk, arm, leg, and feet. Sun-exposed sites:
head and neck.
XAF1, XIAP-associated factor 1.
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Figure4
XIAP-associated factor 1 (XAF1) expression is reduced in both
nucleus and cytoplasm of melanoma cells. The percentage of tumor
cells containing nuclear staining (a) and cytoplasmic staining (b) are
significantly less compared to normal nevi. po0.0001 for both, Mann–
Whitney test.
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Discussion
In this study, we sought to determine the role of XAF1 in the
development and progression of melanoma. We started by
analyzing the XAF1 mRNA expression level in melanoma
cell lines and found that XAF1 transcript was either absent
or reduced in 15 of the 16 melanoma cell lines examined
(Fig 1). In contrast, the level of XAF1 mRNA in normal human
melanocyte was considerably higher. The reduced expres-
sion of XAF1 in melanoma cells was confirmed by immuno-
fluorescent staining (Fig 2). Using the TMA technology, we,
for the first time, found a significant reduction of the XAF1
staining intensity in primary melanomas (Fig 3). In addition,
XAF1 reduction occurred both in the nucleus and cytoplasm
of tumor cells (Fig 4a, b). In a recent report, an analysis on
the expression of XAF1 mRNA in 87 primary gastric carci-
nomas also found that expressions of XAF1 in primary
gastric tumors were substantially lower compared with the
non-cancerous tissues (Byun et al, 2003). The differential
expression of XAF1 in benign nevi and melanoma tissue
strongly implicates that XAF1 plays a role in the malignant
transformation process.
Previous biochemical study revealed that XAF1 was able
to inhibit the anti-caspase activity of XIAP (Liston et al,
2001). Adenoviral delivery of XAF1 has also been shown to
enhance the sensitivity of etoposide-induced apoptosis
(Liston et al, 2001). Since the decision of whether a cell
undergoes apoptosis depends on the balance between pro-
and anti-apoptotic regulators, tumor-specific reduction of
XAF1 may lessen the check on the anti-caspase activity of
XIAP and potentially tilt the balance toward enhanced cell
survival. The loss of XAF1 expression may also increase the
threshold necessary for effective killing of cancerous cells
by chemotherapeutic agents, and together with other fac-
tors, may contribute to the chemoresistance in melanoma.
In support of this, Liston et al (2001) showed that lowering
the expression of XAF1 by infecting XAF1 expressing cells
with anti-sense XAF1 adenovirus conferred significant pro-
tection to etoposide killing.
It was previously reported that XAF1 could sensitize me-
lanoma cells to tumor necrosis factor-related apoptosis-in-
ducing ligand (TRAIL)-induced apoptosis (Leaman et al,
2002). TRAIL is an interferon-stimulated gene (ISG) whose
expression is induced by interferons (IFN) (Leaman et al,
2003). Interestingly, XAF1 has also been identified as an ISG
and its transcription level was upregulated by IFN-a2 and
IFN-b (Leaman et al, 2002, 2003). The degree of TRAIL
sensitization correlated with the level of XAF1 expressed
(Leaman et al, 2002). Thus, the reduced expression of XAF1
in majority of melanoma tissues as identified in our study
and/or the failure to IFN induction may negatively impact the
effectiveness of using IFN-a2 as an adjuvant therapy for
advanced melanoma and could possibly explain for the lack
of improvement on overall survival in the past randomized
trials (Eggermont and Punt, 2003).
Given the fact that XAF1 resides predominantly in the
nucleus, the reduction of XAF1 expression in the nucleus
may contribute to malignant cell transformation. Liston et al
(2001) has shown that XAF1 could trigger the relocalization
of XIAP from the cytoplasm to the nucleus. The shuttling of
XIAP to the nucleus prevents XIAP from binding to the ca-
spases, so that the apoptosis will proceed unimpeded in
response to apoptotic stimuli. In contrast, loss of XAF1 nu-
clear expression in tumors may increase the functional pool
of XIAP in the cytoplasm, which in turn inactivates the ca-
spases and inhibits apoptosis. Since programmed cell
death is a self-protective mechanism to remove unwanted
and severely damaged cells to maintain the genomic sta-
bility, aberrant regulation in the apoptotic pathways could
lead to accumulation of gene mutations causing abnormal
cell proliferation and malignant cell transformation. It is,
however, currently not known whether XAF1 possess other
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Figure 5
Correlation between nuclear XIAP-associated factor 1 (XAF1) ex-
pression with tumor thickness and 5 y patient survival. (a) XAF1
nuclear expression did not correlate with tumor thickness (p¼ 0.156,
Kruskal–Wallis test). Neither XAF1-staining intensity (b) nor the XAF1
nuclear positivity (c) correlated to 5-y overall patient survival. p>0.05 for
both, log-rank test.
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nuclear functions that contribute to its proapoptotic action
beside the ability to sequester XIAP.
Byun et al (2003) found that abnormal reduction of XAF1
mRNA was significantly more prevalent in advanced gastric
tumors compared with tumors of early stage, suggesting
that the loss of XAF1 expression correlates with tumor pro-
gression. In spite of XAF1 expression being markedly re-
duced in melanoma, our results did not show a statistically
significant correlation between reduction of XAF1 nuclear
expression and tumor thickness (Fig 5a). A greater sample
size for the advanced melanoma and the inclusion of met-
astatic melanoma samples will be helpful in determining
whether the loss of XAF1 expression correlates with me-
lanoma progression. In addition, reduction of XAF1 in me-
lanoma did not associate with the poorer 5-y patient
survival (Fig 5b, c). We speculate that due to the complex-
ity of apoptotic pathways, a change in cell behavior will
probably require multiple levels of dysregulation. Thus, the
reduction of XAF1 expression in primary melanomas is likely
part of the many alternations acquired during melanoma
progression or serves to prime for other malignant events
that seriously hamper patient survival. Beside XAF1, other
defects in the apoptotic pathway have been implicated in
melanoma pathogenesis. When compared with melanocytic
cells, melanoma cells differentially express elevated levels
of anti-apoptotic molecules including members of Bcl-2
family (Bcl-XL and Mcl-1), and the IAP (XIAP and livin)
(Bowen et al, 2003). On the other hand, the proapoptotic
Bcl-2 member, Bax, was found to be underexpressed in
melanoma cells (Bowen et al, 2003). Interestingly, primary
cultures of melanoma patient expressing high level of the
IAP member livin were resistant to etoposide (Nachmias
et al, 2003). In addition, patients that died or had disease
progression, while on chemotherapy, showed intermediate
to high levels of livin (Nachmias et al, 2003). In contrast,
disease-free patients were livin negative, whereas chemo-
responsive patients either showed no expression or weak
expression of livin (Nachmias et al, 2003). Another IAP pro-
tein, survivin, was also found to be strongly expressed in
invasive melanomas and metastatic lesions, but was unde-
tectable in normal melanocytes (Grossman et al, 1999;
Bowen et al, 2003). The role of survivin on melanoma de-
velopment has been illustrated by the reduction of tumori-
genicity in melanoma xenograft of topotecan-treated mice
when subjected to ribozyme-mediated downregulation of
survivin (Pennati et al, 2004). Due to the complexity of reg-
ulatory pathways in the apoptosis process, further studies
on the expression profiles of pro- and anti-apoptotic pro-
teins in the same set of melanoma biopsies may provide
useful information on the prognostic value of these proteins.
In summary, our study has demonstrated that XAF1 ex-
pression is dramatically reduced in melanoma. Our study
prompts for further characterization of the functional role
of XAF1 in the chemoresistance and progression of
melanoma.
Material and Methods
Cell culture All melanoma cell lines were cultured in Dulbecco’s
Modified Eagle Medium supplemented with 10% fetal bovine se-
rum (Invitrogen, Burlington, ON, Canada). Normal human epider-
mal melanocyte were cultured in melanocyte basal medium
supplemented with 50 ng per mL amphotericin B, 1.0 ng per mL
basic fibroblast growth factor, 0.004 mL per mL bovine pituitary
extract, 50 mg per mL gentamicin, 5.0 mg per mL hydrocortisone,
5.0 mg per mL bovine insulin, and 10 ng per mL phorbol 12-my-
ristate 13-acetate (PromoCell, Heidelberg, Germany). All cells were
maintained in 5% CO2 at 371C.
RT-PCR analysis Total RNA of all melanoma cell lines and normal
human melanocytes was extracted with TriZol reagent (Invitrogen).
RNA concentrations were measured with a spectrophotometer at
260 nm. Two micrograms of total RNA was reverse transcribed into
cDNA using 1 mM oligo(dT)12–18 primers, 4 U Omniscript reverse
transcriptase (Qiagen, Mississauga, ON, Canada) and dNTP mix
(10 mM each) in the presence of 10 U RNase inhibitor in a total
volume of 20 mL. The RT mix was incubated at 371C for 1 h fol-
lowed by a 5 min heating at 931C to inactivate the enzyme. The
PCR reaction included 1.0–2.5 mL of the first strand reaction prod-
uct, 5 mM dNTP mix, 2.5 U Taq DNA polymerase and 10  Qiagen
PCR buffer (Qiagen) together with 0.5 mM each of XAF1 specific
primers (forward: 50-GAGCACCAGCAGGTTGGGTG-30; reverse:
50-AATCATTTGGTTGCAATAAT-30). Amplification was carried out
as follows: (a) initial denaturation at 941C for 3 min, (b) denaturation
at 941C for 1 min, (c) annealing at 50.61C for 1 min, (d) polymerization
at 721C for 1 min. The reaction was repeated for 35 cycles followed
by final polymerization at 721C for 10 min. Samples were then elect-
rophoresed on a 2% agarose gel containing 0.5 mg mL of ethidium
bromide. The XAF1 specific primers generate a 324 bp product as
visualized under ultraviolet light. (Zeiss, Go¨ttingen, Germany).
Immunoﬂuorescent staining Cells were grown on cover slips at
a density of 2  104 cells per well in a six-well plate for 24 h. After
washing twice in cold phosphate-buffered saline (PBS), cells were
fixed and permeabilized with 2% paraformaldehyde, 0.5% Triton
X-100 in PBS at 41C for 30 min. Slides were washed twice with
PBS and cells were blocked overnight with normal goat serum at
41C, followed by staining with rabbit anti-XAF1 antibody (a kind gift
from Dr Robert G. Korneluk, University of Ottawa) at a dilution of
1:25 for 1 h at room temperature. The cells were washed for 5 min
in three changes of PBS and incubated at room temperature for 1 h
with Cy3-conjugated goat anti-rabbit IgG at 1:500 dilution (Jack-
son ImmunoResearch, West Grove, Pennsylvania). DNA contents
were stained with 2 mg per mL Hoechst 33258 for 1 min. After
washing, the cells were mounted in Permount mounting media
(Fisher Scientific, Ottawa, ON, Canada), and visualized under a
Zeiss Axioplan 2 microscope (Zeiss, Go¨ttingen, Germany).
Tissue microarray The construction and composition of the me-
lanoma TMA were described previously (Dai et al, 2003). Briefly,
formalin-fixed, paraffin-embedded tissue blocks containing 46 be-
nign nevi and 87 primary melanomas were retrieved from the 1990–
1997 archives of the Vancouver General Hospital Department of
Pathology. The use of human skin tissues in this study was ap-
proved by the medical ethical committee of the University of British
Columbia and was performed in accordance with the Declaration
of Helsinki Guidelines. For each case, the most representative
tumor area was selected and marked on hematoxylin- and eosin-
stained slides. To ensure an adequate representation of the whole
tumor tissue, three or fewer cylindrical core tissue biopsies, de-
pending on the size of nevi and tumors, were obtained from cor-
responding marked area of each specimen and transferred to the
recipient block at defined array positions using a Tissue Arrayer
(Beecher Instruments, Sun Prairie, Wisconsin) with a 0.6 mm nee-
dle. Multiple 4 mm thick sections were cut from the recipient block
using a Leica microtome (Leica Microsystems, Inc., Richmond Heil,
Ontario, Canada) and mounted on microscope slides.
Immunohistochemistry TMA slides were deparaffinized by heat-
ing at 551C for 30 min followed by three washes with xylene. Tis-
sues were rehydrated in a series of ethanol washes and rinsed with
PBS. Antigen retrieval was carried out by microwaving the slides at
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high power in 10 mM citrate buffer (pH 6.0) for 4 min. Endogenous
peroxidase activity was quenched with 0.3% hydrogen peroxide in
PBS for 20 min. Non-specific binding was blocked with normal goat
serum for 30 min. XAF1 immunoreactivity was studied using the
rabbit anti-XAF1 antibody (a kind gift from Dr Robert G. Korneluk,
University of Ottawa) at a dilution of 1:25. The antibody was applied
for 1 h at room temperature. The slides were washed with PBS and
then incubated with a biotinylated anti-rabbit antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) for 30 min. After washing with PBS,
the slides were incubated with horseradish peroxidase-conjugated
streptavidin (Santa Cruz Biotechnology) for 45 min. Following the
wash with PBS, the signals were developed with 3,30-diaminobenzi-
dine substrate (Vector Laboratories, Burlington, ON, Canada) for
5 min and counterstained with hematoxylin. The slides were dehy-
drated and sealed with coverslips. Negative control was performed
by omitting the primary XAF1 antibody.
Evaluation of immunostaining 46 benign nevi and 87 primary
melanoma cases were included in the array. Of the 46 nevi case,
informative staining was obtained in 40 cases. Of the 87 primary
melanoma cases, informative tumor staining and complete clinical
pathological information were available for 70 cases. For survival
analysis, 69 patients that have their 5-y overall survival information
and informative tumor staining available were included in the eval-
uation. Melanoma staging was classified according to Breslow
thickness (Marghoob et al, 2000); p0.75 mm (low risk), 0.76–1.5
mm (intermediate risk), 1.51–4.0 mm (high risk), and >4.0 (very high
risk). Tissue scoring was carried out simultaneously by three in-
dependent observers (including one dermatopathologist) and a
consensus score was reached for each core. Overall intensity was
assessed on a four-point scale: negative (0), weak (1), moderate
(2), or strong (3), regardless of tissue type. In addition, the per-
centage of cells showing positive staining in the nucleus and cy-
toplasm was assessed independently. For both nuclear and
cytoplasmic staining, we defined the staining as strongly positive
if >50% of cells contained XAF1 in the respective compartment,
weakly positive if p50% of cells showing XAF1 staining, and neg-
ative if complete absence of staining. For cases in which multiple
biopsy cores were available, 80% of the biopsies had uniform
staining for both normal and tumor tissues. In the event of incon-
sistent staining for either normal and tumor tissue, the highest
score was used for statistical analysis. The percentages of cells
showing positive XAF1 staining were averaged among the multiple
biopsy cores.
Statistical analysis The level of XAF1 expression in tumors ver-
sus the benign melanocytic nevi was compared using the Pearson
w2 test. The frequency of cells showing positive staining in the
nucleus and cytoplasm, respectively, between nevi and tumor tis-
sues was compared using the Mann–Whitney test. The relationship
between XAF1 expression and clinical pathological parameters,
including gender, age, tumor thickness, location, and histological
subtype was evaluated by w2 test or Fisher’s Exact test, where
appropriate. The percentages of cells showing XAF1 staining in the
nucleus at different thicknesses were compared using Kruskal–
Wallis test. Survival curves were plotted according to Kaplan and
Meier method and comparison of survival times was carried out
with the log-rank test. A p-value of less than 0.05 was considered
to be significant. All statistical analyses were performed with SPSS
standard version 11.5 (SPSS, Chicago, Illinois).
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